Comment

Australia’s life sciences sector has welcomed a major national push to strengthen research, development and innovation, with industry leaders urging coordinated government action to secure the country’s economic and health future.

A coin-sized implantable sensor designed to monitor pressure inside the brain has been approved for use in Australia, offering clinicians a new way to manage hydrocephalus and potentially reducing the need for repeated scans and surgical interventions.

The Sydney-based medical device company announced that its non-renounceable entitlement offer had raised about $2 million and was fully subscribed, including the underwriting commitment from Bell Potter Securities.

Firebrick Pharma has appointed experienced pharmaceutical executive Nilesh Wadhwa to lead its global business development and licensing efforts as the company pushes to rapidly expand international approvals and sales of its Nasodine product range.

The Perth and San Francisco-based biotechnology company announced that discussions with the FDA confirmed key elements of the clinical trial required to support a future New Drug Application for the therapy.

Researchers have confirmed that Kappa Myeloma Antigen and Lambda Myeloma Antigen appear on malignant plasma cells but not on healthy ones, opening the door to treatments that could attack cancer cells with far greater precision while sparing the normal immune system.

Tetratherix (ASX:TTX) has taken a significant step forward in the development of its prostate cancer technology, advancing its Tutelix spacer toward an international pivotal trial following encouraging early clinical results and the successful completion of a Series A capital raise by its joint venture partner.

Mesoblast (ASX:MSB) has appointed physician scientist Dr Teresa Montagut to lead its clinical development and medical affairs efforts, strengthening the company’s leadership team as it expands its portfolio of cell therapies for inflammatory diseases.

Patrys (ASX:PAB) has taken significant steps toward advancing a potential new treatment for delirium into human clinical trials, including manufacturing and regulatory preparations for its experimental drug candidate RLS-2201.

Australian immuno-oncology company Imugene (ASX:IMU) has moved to accelerate development of its lead cancer therapy after reporting encouraging clinical results, while launching a capital raising to fund the next phase of trials.

The $1.5 billion project builds on more than $3 billion the global biopharmaceutical company has already invested in its United States operations since 2018 and is expected to create at least 300 new jobs alongside hundreds of construction roles.

Telix Pharmaceuticals (ASX:TLX) has reported positive early outcomes from the first part of its global Phase 3 ProstACT study, marking an important step in the development of a new targeted treatment for advanced prostate cancer.